TRACON said that the study, ENVASARC, failed to meet its primary endpoint of an overall response rate of 11%. According to the company’s website, the study, also known as NCT04480502, was a ...

Baird has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an 'outperform' rating and a $10 price target. In a note to clients, Baird's ...

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report report published on Tuesday morning.

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was ...

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...

I-Mab, a clinical-stage biopharmaceutical company with U.S. offices in Gaithersburg, Tuesday was awarded an arbitration victory stemming from a $200 million dispute with Tracon Pharmaceuticals ...

Tracon stock slumps ~15% after I-Mab gets favorable ruling in arbitration Apr. 25, 2023 6:01 AM ET I-Mab (IMAB) Stock , TCON Stock By: Ravikash Bakolia , SA News Editor AmnajKhetsamtip ...

The total radio coverage of Nigeria (TRACON)on VHF has been completed, Managing Director of the Nigerian Airspace Management Agency (NAMA), Mazi Nnamdi Udoh has said. He said the Kano phase of the ...

Analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a ...